| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Endogenous metabolite (Metabolic tracer)
|
|---|---|
| ln Vitro |
As a stable isotope-labeled compound, DL-Glutamic acid-d3 is incorporated into metabolic pathways of glutamic acid. It is used as an internal standard for LC-MS/MS quantification of glutamic acid in biological samples, enabling precise measurement of this fundamental metabolite.
|
| ln Vivo |
The compound is used as a tracer for metabolic flux studies. Glutamic acid is a conjugate acid of glutamate, a key intermediate in amino acid metabolism and neurotransmission. The deuterated form allows tracking of glutamic acid through the TCA cycle and glutamate-glutamine cycle.
|
| Enzyme Assay |
The compound is characterized by isotopic enrichment and chemical purity. It is not tested in enzyme or receptor binding assays. Standard characterization includes NMR to confirm deuterium positions, LC-MS to assess isotopic purity, and HPLC to verify chemical purity.
|
| Cell Assay |
For cellular metabolic studies, cells are cultured in media containing DL-Glutamic acid-d3. After defined intervals, samples are collected and analyzed by LC-MS to quantify the incorporation of labeled glutamic acid into downstream metabolites including alpha-ketoglutarate, GABA, and glutathione.
|
| Animal Protocol |
Animal studies using DL-Glutamic acid-d3 can trace glutamate metabolism in brain and peripheral tissues. The labeled compound is administered via intraperitoneal injection or oral gavage. At various time points, tissues are collected and analyzed by mass spectrometry to follow metabolic flux.
|
| ADME/Pharmacokinetics |
The compound is not evaluated for PK as a drug. However, metabolism and clearance of the labeled glutamic acid can be traced in PK studies to understand the turnover of the endogenous metabolite pool. Deuterium labeling increases stability for LC-MS detection.
|
| Toxicity/Toxicokinetics |
As a stable isotope-labeled endogenous metabolite, the compound has low toxicity at tracer doses. The non-labeled DL-Glutamic acid is an amino acid with excellent safety and tolerability. Overdoses of glutamic acid can cause excitotoxicity in neuronal systems.
|
| References | |
| Additional Infomation |
DL-Glutamic acid-d3 is an analytical reference material and metabolic tracer for LC-MS/MS applications. It is not a drug and has no regulatory approval for human use. It is strictly a research chemical for academic and pharmaceutical development laboratories.
|
| Molecular Formula |
C5H6D3NO4
|
|---|---|
| Molecular Weight |
150.15
|
| Exact Mass |
150.071
|
| CAS # |
96927-56-9
|
| Related CAS # |
DL-Glutamic acid;617-65-2
|
| PubChem CID |
71309806
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
333.8±32.0 °C at 760 mmHg
|
| Melting Point |
185 °C (dec)(lit.)
|
| Flash Point |
155.7±25.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.522
|
| LogP |
-1.43
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
10
|
| Complexity |
145
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])(CC([2H])(C(=O)O)N)C(=O)O
|
| InChi Key |
WHUUTDBJXJRKMK-UHVFUKFASA-N
|
| InChi Code |
InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/i2D2,3D
|
| Chemical Name |
2-amino-2,4,4-trideuteriopentanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :≥ 17.86 mg/mL (~118.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.6600 mL | 33.3000 mL | 66.6001 mL | |
| 5 mM | 1.3320 mL | 6.6600 mL | 13.3200 mL | |
| 10 mM | 0.6660 mL | 3.3300 mL | 6.6600 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
